Immunology
🇺🇸 FDA Page 2FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Gain critical insights into global immunology drug development, market trends, and regulatory landscapes. Inform your pharma BD and investment strategy.
Showing 13–24 of 50 articles
Cadrenal Therapeutics CAD-1005 Gets FDA Guidance for Phase 3 Trial in Heparin-Induced Thrombocytopenia
RedHill's RHB-204 Shows Comparable Efficacy to RHB-104 in Crohn's Disease MAP Treatment Development
IgA Nephropathy Market to Reach New Heights by 2036 as Novartis Zigakibart and Novel Immunotherapies Drive Growth
Teva's PONLIMSI Biosimilar Receives FDA Approval for All Prolia Indications as Q1 2026 Results Show Strong Growth
InnoCare Pharma Begins Phase III Trial of Orelabrutinib for Systemic Lupus Erythematosus Treatment
Vanda Pharmaceuticals' Imsidolimab Shows Efficacy for Generalized Pustular Psoriasis in NEJM Evidence Study
AbbVie Submits FDA Application for Upadacitinib (RINVOQ) to Treat Severe Alopecia Areata
Cellenkos Receives FDA Clearance for CK0801 Phase 2 Trial in Aplastic Anemia
AstraZeneca's SAPHNELO Autoinjector Approved by FDA for Self-Administration in Lupus Treatment
Intellia Therapeutics Submits FDA Application for Lonvo-Z, First CRISPR Gene Therapy for Hereditary Angioedema
Aclaris Therapeutics ATI-052 Phase 1a Trial Results and ATI-2138 Lead Indication Update Set for April 28, 2026
OSE Immunotherapeutics' Pegrizeprument (VEL-101) Receives FDA Orphan Drug Designation for Heart Transplant Rejection Prevention